Form D · Biotechnology
Annidis Corp
Ottawa, A6 · CIK 0001523828
Offering snapshot reported Mar 29, 2012 · SEC filing
- Reported sold
- $50K Offering amount: $50K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Mar 16, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 29, 2012 | Initial | $50,000 | No comparison | 2 | SEC filing |
| Jun 24, 2011 | Initial | $75,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-175887
The total above reflects the total U.S. offering. The total overall offering is CDN $2,020,000.
Source: Form D, filed Mar 29, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Baker | Director |
| Michael Crowley | Director |
| Robert Devenyi | Director |
| Timothy Mc Cunn | Director |
| Michael Mueller | Director |
| Zeljiko Ribaric | Director, Executive |
| Zeljko Ribaric | Director, Executive |
| Gerald Slemko | Director, Executive |
| Rony Thomas | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
245 2650 Queensview Drive
Ottawa, A6, K2B 8H6
Ottawa, A6, K2B 8H6